Back to Search Start Over

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.

Authors :
Takamori, Shinkichi
Matsubara, Taichi
Haratake, Naoki
Toyokawa, Gouji
Fujishita, Takatoshi
Toyozawa, Ryo
Ito, Kensaku
Yamaguchi, Masafumi
Taguchi, Kenichi
Okamoto, Tatsuro
Seto, Takashi
Source :
Frontiers in Oncology; 8/23/2021, Vol. 11, p1-6, 6p
Publication Year :
2021

Abstract

Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fusion-positive lung adenocarcinoma occurs in 1%–2% of cases. Clinical trials of multikinase inhibitors, including cabozantinib, vandetanib, sorafenib, and lenvatinib, that inhibit RET oncogene activity have shown their antitumor efficacy. Recently, RET inhibitors such as pralsetinib and selpercatinib that are specialized for RET kinase have also been developed, and their efficacy was investigated in previous clinical trials (BLU-667 and LOXO-292). In this review, we summarized the effects and adverse events of multikinase and selective RET inhibitors and the various diagnostic techniques for RET gene fusion. In the perspective part, we focused on the unsolved issues on treatment for RET fusion-positive lung cancer and future developments. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2234943X
Volume :
11
Database :
Complementary Index
Journal :
Frontiers in Oncology
Publication Type :
Academic Journal
Accession number :
152060893
Full Text :
https://doi.org/10.3389/fonc.2021.704084